Britain and America have hammered out a important trade agreement that will keep no levies on British pharmaceutical shipments going into the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to raise funding on drugs through the public health system. This commitment guarantees that duties on these crucial exports will remain at zero for a duration of three years.
This agreement is in response to previous threats to significantly raise import taxes on branded drug imports, with potential rates discussed reaching double the cost.
"This deal between the UK strengthens the worldwide climate for cutting-edge drugs and brings much-needed equity to transatlantic drug exports," an announcement noted.
Commercial Importance
Drugs constitute one of the Britain's most significant goods shipped to the US, which is clearly the primary destination for major British pharmaceutical firms.
Statistics show that in the one-year period to the end of last September, the UK shipped drugs worth £11.1bn to the US. This amount made up 17.4% of all goods exports in that span.
"This deal secures jobs, stimulates capital expenditure and sets the stage for the UK to emerge as a worldwide center for medical research," a government official commented.
Specific NHS Changes
The agreement involves several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the affordability limit at which it judges new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a goal to raise total public funding on drugs from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to control costs will be limited at 15%. In the past, repayments were more than 20%.
Industry Background
The pact follows a long-running row between the drug companies and the British authorities over drug pricing and NHS adoption.
The disagreement were exacerbated by claims that American patients were paying several times more for the identical medicines than people in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been paused or abandoned, while major investments have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had shrunk as a share of its resources over the past decade.
